SAC Meeting Calendar
Newest Background Analyses
Search by Tag
- AAC
- AADPAC
- ACHDNC
- ACPS-CP
- AIDAC
- alogliptin
- AMDAC
- Amgen
- ankylosing spondylitis
- anti-hypertensives
- antibacterial
- APAC
- asthma
- AstraZeneca
- biosimilar
- bladder cancer
- blood donation
- Boehringer Ingelheim
- BPAC
- BRUDAC
- cancer
- Celltrion
- CFTR potentiator
- CLIAC
- CRDAC
- Crohn's disease
- CT-P13
- CTGTAC
- Cystic Fibrosis
- cytolitic
- diabetes
- DODAC
- DSRM
- Duchenne muscular dystrophy
- Eli Lilly
- EMDAC
- epidural steroid injections
- eteplirsen
- ezetimibe
- FDA
- GlaxoSmithKline
- HHS
- high cholesterol
- hypoactive sexual desire disorder
- infection
- infliximab
- influenza
- invasive aspergillosis
- iron deficiency
- ivacaftor
- liraglutide
- major depressive disorder
- melanoma
- Merck
- MIDAC
- monoclononal antibodies
- NDAC
- necitumumab
- neutropenia
- Novartis
- Novo Nordisk
- ODAC
- oncolytics
- opioid
- PADAC
- pain
- panobinostat
- Parkinsons disease
- PCAC
- PCNS
- PCSK9 inhibitor
- PDAC
- PEDAC
- pediatric
- pediatric anesthesia
- Pfizer
- Psoriasis
- psoriatic arthritis
- Purdue Pharma
- RCAC
- reduce CV risk
- reversal of neuromuscular blockade
- RO5503781
- Rockwell Medical
- SACHRP
- Sandoz
- Sanofi Aventis
- Sarepta Therapeutics
- SBFDA
- sugammadex
- Takeda
- talimogene laherparepvec
- testosterone
- testosterone replacement therapy
- Teva
- The Medicines Company
- TSEAC
- vaccines
- Vertex Pharmaceuticals
- VRBPAC
Review of an mmediate-release oral tablet formulation of oxycodone, which is intended to resist common methods of physical or chemical manipulation and to deter intravenous and intranasal abuse, submitted by SpecGx Inc.